We are live on ! Find out more
LRMR icon

Larimar Therapeutics

43 hedge funds and large institutions have $305M invested in Larimar Therapeutics in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more capital inflows, than outflows

Capital inflows: $29M | Capital outflows: $13.6M

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

67% more funds holding in top 10

Funds holding in top 10: 3 → 5 (+2)

38% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 8

13% more funds holding

Funds holding: 38 → 43 (+5)

4.08% more ownership

Funds ownership: 88.7% → 92.79% (+4.1%)

Holders
43
Holders Change
+5
Holders Change %
+13.16%
% of All Funds
0.76%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.09%
New
11
Increased
11
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

LRMR Hedge Fund Activity: Q4 2020 in Review

43 of the 5,680 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q4 2020, worth a combined $305M — up 48% from $207M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new LRMR positions and 6 closed out — a net gain of 5 holders — while 11 added to existing stakes and 8 trimmed.

The largest buyer was Logos Global Management, adding an estimated $7.72M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $5.19M sold.

  • 43 institutional investors held Larimar Therapeutics (LRMR) as of Q4 2020, up from 38 in Q3 2020.
  • Funds reported $305M of Larimar Therapeutics stock for Q4 2020, up 48% quarter-over-quarter.
  • 11 funds opened new Larimar Therapeutics positions in Q4 2020 and 6 closed out, a net change of +5 holders.
  • The largest Larimar Therapeutics buyer in Q4 2020 was Logos Global Management, an estimated $7.72M added.
  • The largest Larimar Therapeutics seller in Q4 2020 was Sphera Funds Management, an estimated $5.19M sold.

Based on aggregated 13F filings for Q4 2020.